Contract analysis

1. Scope of Engagement The Firm is retained to provide legal advice and services to the Company in connection with the preparation, review, and submission of a supplemental New Drug Application ("sNDA") to the United States Food and Drug Administration ("FDA"). The sNDA will seek approval to add a new indication — specifically, the treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates

2. Staffing The following attorneys will be principally responsible for the services rendered under this engagement: Joel Strauss, Partner — Mr. Strauss will serve as the Responsible Partner for this matter and will have overall supervisory responsibility for the engagement. Miriam Calloway, Partner — Ms. Calloway will serve as the Billing Partner and will be available to advise on regulatory strategy and labeling ma

3. Fees and Billing Professional services rendered in connection with this engagement will be billed at the following blended hourly rates: These rates are the Firm's current standard rates for this type of engagement and are effective as of the date of this letter. The Firm reserves the right to adjust its standard billing rates from time to time; provided, however, that the Firm will provide the Company with at lea

4. Matter Number This engagement has been assigned the following internal matter number: 1018-00005 We respectfully request that the Company reference this matter number on all correspondence, invoices, payments, and other communications directed to the Firm in connection with this engagement. Use of the matter number will facilitate the accurate allocation of time and expenses and will help ensure the prompt and eff

5. Confidentiality The Firm acknowledges that, in the course of this engagement, it may receive or have access to confidential and proprietary information of the Company, including, without limitation, clinical trial data, preclinical and nonclinical study results, trade secrets, proprietary formulations, regulatory strategy documents, internal communications, and other information that the Company regards as confide

6. Conflicts of Interest Prior to undertaking this engagement, the Firm conducted a thorough review of its current and recent client representations in accordance with its standard conflicts-checking procedures and the applicable Rules of Professional Conduct. Based on that review, the Firm has not identified any conflict of interest that would preclude or materially limit the Firm's ability to represent the Company

7. Termination Either party may terminate this engagement at any time, with or without cause, upon thirty (30) days' prior written notice to the other party. In the event of termination by either party, the Company shall remain responsible for payment of all professional fees and disbursements incurred by the Firm through and including the effective date of termination. Upon termination, the Firm will cooperate with

8. Governing Law This engagement letter and the terms and conditions set forth herein shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflict-of-laws principles. We hope that this letter accurately reflects the terms of our engagement. If the foregoing is consistent with your understanding, please so indicate by signing and returning a copy of this lette